A national pharmacogenetics testing service
Impact Summary for the General Public
Our research concerning the economics of pharmacogenetic testing: (i) led to the development of a CE-marked commercial product with MC Diagnostics, which is used in the Netherlands; (ii) informed the delivery of pharmacogenetics in response to the Welsh Government’s Genomics for Precision Medicine Strategy; and (iii) underpinned the decision of NHS England / Genomics England to pilot a national pharmacogenetics service. This service is relevant to 42 prescribed medications, which are likely to be prescribed to 85% of the population over their lifetimes. If just 1% of eligible patients were tested, representing 42,000 tests annually, 2,800 adverse drug reactions could be avoided.
Category of impact
- Health/Quality of life
Research outputs (6)
- Published
Cost-effectiveness of panel tests for multiple pharmacogenes associated with adverse drug reactions: An evaluation framework
Research output: Contribution to journal › Article › peer-review
- Published
Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout
Research output: Contribution to journal › Article › peer-review
- Published
Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden
Research output: Contribution to journal › Article › peer-review